Recently, Medilo (Shanghai) Pharmaceutical Technology Co Ltd officially settled in the Waigaoqiao Free Trade Zone.
The company focuses on providing one-stop services for sponsors of clinical trials, including research protocol design, full-process project operation management, statistical analysis of data and the application and registration of drugs and devices (including dual submissions in China and the United States).
It has established close collaborations with multiple clinical trial institutions, principal investigators from top-tier hospitals, professors from key universities and a think tank of over 50 multidisciplinary experts, covering the entire process of clinical trials.
Medilo is the first biopharmaceutical enterprise introduced by Shanghai Waigaoqiao Biomedical Industry Development Co Ltd, a subsidiary of the Waigaoqiao Group, since its establishment.
As a wholly-owned subsidiary of the Waigaoqiao Group, the biopharmaceutical company focuses on two main tracks: cross-border R&D and production of cell and gene therapies, and local manufacturing of international medical devices.
It is committed to providing specialized industrial support services for the biopharmaceutical industry, coordinating with financial institutions for investment matchmaking to promote investment attraction and linkage, managing the matching of spatial carriers and accelerating the healthy development of key projects in the free trade zone area.
